A founding cohort, not a customer list.
Four access tiers for pharmaceutical, agritech, and AI organisations. Founding Partner status is offered by invitation, one organisation per commercial domain.
Four tiers. Each built for a different level of strategic commitment.
IsoGentiX is a data infrastructure company. Access to the platform is structured as a tiered licensing model - from API access to full co-development arrangements. Tier selection reflects how central Madagascar's biological intelligence is to your pipeline.
API Access
Structured data delivery. Query the platform without managing a full relationship.
- Permissioned API access to specified species and data layers
- Machine-readable formats (JSON, CSV, FASTA, VCF)
- GUID-linked provenance metadata with every response
- Nagoya-compliant access certificate included
- Standard SLA - shared infrastructure
- Defined query volume per licence term
For: Data science teams, research procurement
Category Licence
Full access across a defined therapeutic, crop, or AI application category.
- All 8 data layers within a defined biological category
- Category-exclusive data delivery window (limited period)
- Intraspecies variation panels included
- Dedicated data delivery and onboarding support
- Quarterly data updates as collection advances
- Sub-licence rights for internal teams and CROs
- Priority access to new species in category
For: Pharma AI teams, agritech R&D, foundation model trainers
Domain Exclusivity
Exclusive access across an entire commercial domain for a defined term.
- Exclusive access in your domain: no competitor receives the same data during exclusivity window
- Full platform - all species, all layers, all variation panels
- Input into species prioritisation for your domain
- Direct data pipeline integration support
- Co-branding options for Nagoya-compliant data provenance
- Dedicated account management and technical support
- Right of first renewal before public or non-exclusive release
For: One partner per domain - Pharma / Agritech / AI
Founding Partner
Co-build the platform. Set the direction. Own the outcome.
- All Tier 2 domain exclusivity rights
- Input into the collection schedule and species selection from day one
- Access to data as it is generated - before full processing
- Bespoke data layer additions negotiated at partnership level
- Co-development rights for derivative products within your domain
- Named acknowledgement in publications and regulatory submissions (if agreed)
- Seat at the IsoGentiX Scientific and Commercial Advisory Council
- Multi-year term with defined renewal architecture
For: Organisations for whom this dataset is strategically central
No financial figures are published on this website. All commercial terms are discussed directly. Contact us to begin that conversation.
This dataset will be built. The question is whether you were first.
The IsoGentiX dataset will exist. Madagascar's endemic flora will be sequenced, annotated, and made commercially accessible. That process is underway. The MEDD framework agreement, the collection infrastructure, and the analytical pipeline are operational.
Founding Partners do not get a discount. They get a head start - and the influence to shape what gets built first. When your primary competitor accesses the same dataset in year three, they will be working with data whose scope and prioritisation was set by you.
Founding Partner status is offered by invitation, one organisation per commercial domain. Pharmaceutical AI, agritech, and AI/LLM foundation model training are distinct domains.
What Founding Partners shape
Which of 12,000 species are sequenced first - driven by your therapeutic targets, crop traits, or AI training requirements.
Additional analytical layers or bespoke characterisation protocols added to the standard 8-layer stack.
Which biomes and substrate types are prioritised in the collection schedule - impacting intraspecies variation coverage.
Data formats, API schema, and pipeline integration specifications tailored to your infrastructure from the outset.
Domain exclusivity is not a premium feature. It is a structural reality.
Once a pharmaceutical organisation holds domain exclusivity on the IsoGentiX dataset, no other pharmaceutical organisation can hold it. The same applies to agritech and AI. This is not artificial scarcity - it is the logical consequence of a dataset with genuine competitive intelligence value.
The competitive landscape in pharmaceutical AI
Leading agritech organisations and a growing number of AI-native pharmaceutical companies are all investing in novel biological training data. Their genomics and computational chemistry teams know that the public databases are saturated - and that the next generation of drug discovery models will be differentiated by the quality and novelty of their training corpus.
Madagascar's endemic flora is one of the few remaining large-scale sources of structurally novel chemistry that is both biologically credible and legally accessible. IsoGentiX is the only organisation building a Nagoya-compliant, specimen-level, multi-omics dataset from it.
The organisation that holds domain exclusivity on this dataset - for whatever term is commercially agreed - will have access to novel chemistry and target intelligence that its competitors do not. That asymmetry is the commercial case for acting first.
Three domains. One Founding Partner each.
Once a Founding Partner slot is confirmed in a domain, that domain moves to Tier 2 Domain Exclusivity for the next entrant - with a defined time delay before any competitive access is considered. The first mover advantage is a strategic commercial choice.
Commercial principles that protect both sides.
No figures on the web
Commercial terms are not published publicly. All tier pricing, exclusivity terms, and contract structures are discussed directly. This protects both parties and allows terms to reflect strategic fit, not catalogue pricing.
Nagoya compliance built in
Every licence includes a Nagoya compliance certificate covering the specimen provenance chain, benefit-sharing record, and MEDD authorisation reference. Partners do not need to audit the compliance record - it is delivered as part of the data package.
Data first, with more to come
IsoGentiX licenses data products as structured digital datasets. Physical specimens remain in Madagascar, deposited with the national herbarium under MEDD oversight. Biological specimen access for validated research partners - fully permitted and legally documented - is available as an additional service on request.
Long-term architecture
The dataset grows over time. Commercial agreements are structured to reflect this - data delivery schedules, renewal rights, and new-species access terms are defined at the outset, not renegotiated annually.
The conversation begins with a briefing.
We do not publish commercial terms. We discuss them - with organisations for whom this dataset is genuinely strategically relevant. If that is your organisation, we will make the briefing worth your time.